Tag
This article explores how CD7 CAR-T therapy leads to EBV-positive lymphoproliferative disorder by revealing CD7-negative T cell dysfunction, immunosuppressive macrophage niches, and EBV-driven B cell transformation through multi-omic techno
This study provides a comprehensive single-cell immune atlas of multiple myeloma, revealing dynamic tumor microenvironment ecotypes linked to disease progression, immune dysfunction, and treatment response, offering new avenues for precisio
FGF18 produced by stromal fibroblasts promotes AML progression via FGFR3-mediated AKT-mTOR signaling, forming a feed-forward loop that impairs CD8+ T-cell immunity. Neutralizing FGF18 synergizes with PD-1 blockade, suggesting a novel therap
This study presents a comprehensive single-cell RNA-sequencing atlas of CTCL, identifying oncogenic transcriptional programs and immune microenvironment features that offer new therapeutic targets for advanced-stage disease.
This article explores the pivotal role of IGF2BP2, an N6-methyladenosine reader, in driving tumor growth and immune evasion in peripheral T-cell lymphoma, highlighting its potential as a dual-action therapeutic target.
High expression of neurotensin receptor 1 (NTSR1) defines an immune-cold colorectal cancer subtype linked to worse outcomes by creating mechanical and biological barriers that exclude T-cell infiltration, highlighting a novel immunotherapeu
This study elucidates transcriptomic differences between primary gastric cancers and peritoneal metastases, revealing distinct tumor microenvironments and molecular pathways, highlighting potential targets for improved diagnosis and therapy
Spatial multimodal profiling reveals two macrophage-defined ENKTL subgroups with distinct tumor-myeloid interactions influencing prognosis and potential immunotherapy targets.
BIA-ALCL is a heterogeneous T cell lymphoma marked by immunosuppressive tumor microenvironments that promote tumor survival and proliferation, revealing potential targets for advanced disease therapy.
NEK9 upregulation in hepatocellular carcinoma promotes immune evasion by enhancing PD-L1 expression and recruiting suppressive myeloid cells. Novel NEK9 inhibitors synergize with PD-L1 blockade, remodeling the tumor microenvironment and imp
Pancreatic fibrosis activates Schwann cells via nuclear mechanosensing, promoting a protumorigenic environment that enhances pancreatic cancer progression, offering novel microenvironment-targeted therapeutic insights.
This study found that advanced high-grade serous ovarian cancers from short-term survivors had more fibroblasts and stromal invasion signals, while tumors from long-term survivors showed stronger immune pathways, suggesting the tumor microe
A large whole-genome sequencing study found tumor-infiltrating clonal hematopoiesis in 18.4% of solid tumors, linked to older age, prior cytotoxic chemotherapy, and worse overall survival, with particularly strong associations in breast can
Patient-derived medullary thyroid cancer models preserved tumor heterogeneity, microenvironmental stem-like features, and variable tyrosine kinase inhibitor response, supporting more personalized preclinical testing.
This review examines how low-dose gemcitabine and cisplatin (LDGC) synergize with anti-PD-L1 therapy in intrahepatic cholangiocarcinoma by reprogramming immunosuppressive SPP1+ macrophages and enhancing CD8+ T-cell cytotoxicity through STAT
PALACE‑2 reports that preoperative pembrolizumab combined with chemoradiotherapy produced a 43.2% pathologic complete response in resectable, locally advanced esophageal squamous cell carcinoma, with acceptable short‑term survival and a hig
A novel Mn-based nanoplatform, LT@MnO@MON-HA (LMMH), responsive to tumor microenvironment triggers metabolic disruption and robust cGAS-STING activation, potentiating chemodynamic therapy and immunotherapy for improved tumor suppression.
Manganese and its nanoparticles play a pivotal role in cancer immunotherapy by modulating immune pathways, reshaping the tumor microenvironment, and serving as effective adjuvants and drug carriers, offering promising avenues to overcome cu
